Septerna, Inc. - 8-K Filing
Septerna selects SEP-204 as development candidate for Graves’ disease and TED with Phase 1 clinical trial planned for Q1 2027. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Septerna selects SEP-204 as development candidate for Graves’ disease and TED with Phase 1 clinical trial planned for Q1 2027. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)